Truemed and ThrivePass Partner to Expand Access to Healthcare Through HSA/FSA Dollars 
Windtree Receives Offer for Its Preclinical Oncology Drug Candidate
Company to receive $7.0 million up front for its preclinical oncology drug candidate Up to $130.0 million in milestone payments starting...
Lisata Therapeutics to Present at the 2025 BIO International Convention
BASKING RIDGE, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Veru to Participate in the Virtual BTIG Obesity Health Forum
MIAMI, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
GraceMed announces appointment of Dan Pawliw as Chief Executive Officer
Dan Pawliw headshot Dan Pawliw, GraceMed's new CEO TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- GraceMed, a leading consolidator in...
Intelligent Bio Solutions Expands U.S. Forensic Market Presence, Seeks FDA Clearance for Breakthrough Fingerprint Drug Testing
SMARTOX has deployed over 50 of INBS’ Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including more...
Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada
Transaction brings OSA diagnostic revenue to Vivos, plus Vivos’ highly effective OSA treatment options to thousands of potential patients in...
OKYO Pharma to Present at the Bio International Convention
LONDON and NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
Artelo Biosciences Announces Reverse Stock Split
Shares Expected to Begin Trading on a Split-Adjusted Basis on June 13, 2025SOLANA BEACH, Calif., June 11, 2025 (GLOBE NEWSWIRE)...
IntelGenx Announces Rebranding to Nualtis, Signaling Strategic Evolution and Renewed Vision
MONTREAL, June 11, 2025 (GLOBE NEWSWIRE) -- IntelGenx, a leader in oral thin film drug delivery, today announced its official...
AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical’s SCD Therapy to Advance Breakthrough Burn and Sepsis Research
$2 million in DoD funding enables the evaluation of SeaStar Medical’s SCD therapy in the setting of severe burns, inhalation...
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
In Patients Receiving a Minimum of 55 mCi an Average 5.4 Months of PFS was Observed: Twice the Reported 2.25...
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline...
Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders
Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on...
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE...
Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders
Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on...
vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series
HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on...
Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing
Facility provides additional funding for next steps of the Company’s growth, including the expected launch of bezuclastinib in 2026 On...
R1 Expands Finance and Corporate Development Teams with New Appointments
Chris Ricaurte Appointed as Chief Financial Officer and Dan Bise Joins as EVP of Corporate Development and Strategy Reflects R1’s...
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
—Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— —Preparations for the Nebokitug PSC Phase...
Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04
Engages with Cytel’s Machine Learning Technology on Data Analysis and Phase 3 Trial DesignGLEN ALLEN, Va., June 11, 2025 (GLOBE...